Filing Details

Accession Number:
0001104659-20-057631
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-06 21:31:41
Reporting Period:
2020-05-04
Accepted Time:
2020-05-06 21:31:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1264587 Stemline Therapeutics Inc STML Pharmaceutical Preparations (2834) 450522567
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1797467 Robert Francomano C/O Stemline Therapeutics, Inc.
750 Lexington Avenue, Eleventh Floor
New York NY 10022
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-05-04 272 $11.51 197,658 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. In connection with the vesting of 1,878 shares on May 2, 2020 a total of 272 shares were sold by the Company on May 4, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
  2. Reflects the weighted average sale price. The range of prices for the shares sold on May 4, 2020 was $11.81 to $12.02. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
  3. Of the shares listed, 144,425 shares are restricted stock.